Drugs / Pandemic flu H5 HA mRNA SD2 vaccine
Pandemic flu H5 HA mRNA SD2 vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06907511 | Apr 2025 → Dec 2026 expected | — | Sanofi | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pandemic flu H5 HA mRNA SD2 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06907511 ↗ |
| Modality | Messenger RNA (mRNA) | “H5 messenger ribonucleic acid (mRNA) vaccine” NCT06907511 ↗ |
| Route | Intramuscular | “Route of Administration: Intramuscular injection” NCT06907511 ↗ |